RTN4R and prostate carcinoma: In order to assess the reproducibility of obtained results, the therapeutic performance of tCoa-NGR fusion protein was evaluated in two animal models: immune-competent BALB/c mice bearing murine 4T1 mammary carcinoma allografts, and human PC3 prostate cancer xenografts in immune-compromised C57BL/6 nude mice.